Skip to main content
. 2016 Jun 21;6:27251. doi: 10.1038/srep27251

Figure 3.

Figure 3

(a) The relative risks of response to HBV vaccine between adults age ≥30 and adults age <30. (b) The relative risks of response to HBV vaccine between adults age ≥30 and adults age <30 grouped by study design. Comparing with adults age <30, the RRs indicate reduced response to HBV vaccine among adults age ≥30 both in cohort and RCT studies.